ReviewCurrent opinion in microbiology2008
Bacteriophage lysins as effective antibacterials.
Review in Current opinion in microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01855048 (A Randomized, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Safety, Pharmacokinetics and Phyarmacodynamcs of a Single Intravenous Dose of N-Rephasin® SAL200, in Healthy Male Valunteers), which is not on this map. Cited by 225 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Safety, Pharmacokinetics and Phyarmacodynamcs of a Single Intravenous Dose of N-Rephasin® SAL200, in Healthy Male Valunteers
Who cites it
225 citing papers in PubMed, 472 citations in OpenAlex.
- Genomic characterization and phage cocktail suppression of a multidrug-resistantApplied and environmental microbiology · 2026Article
- Domain shuffling of endolysin LysKB317 to controlBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- The novel prophage lysin Lys1459 exhibits broad-spectrum antibacterial activity via triple-binding domain.Applied and environmental microbiology · 2026Article
- Integrated computational and experimental benchmarking of Bacillus phage endolysins reveals the relationship between peptidoglycan-fragment recognition descriptors and antibacterial performance.Scientific reports · 2026Article
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Investigation of Recombinantly Produced Endolysins Reveals a Modular Enzyme Shared by Several Enterobacteria Phages to Exhibit Broad-Range Lytic Activity Against Different Orders of Gammaproteobacteria.MicrobiologyOpen · 2026Article
- Enzyme therapy as a promising strategy to overcome multi-drug resistance in pathogens: current advances, key challenges, and future directions.RSC advances · 2026Review
- Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.European journal of medical research · 2026Review
- Autoimmune disease-associated pathobionts: mechanisms and therapeutic potential of phage-based approaches.Frontiers in immunology · 2026Review
- In Vitro Assays for Endolysin Efficacy and Safety Profiling.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Review
- NovelInternational journal of molecular sciences · 2025Article
- Viral Dark Matter: Illuminating Protein Function, Ecology, and Biotechnological Promises.Biochemistry · 2025Review
- Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Engineering a Potent Anti-MRSA Agent: The Development and Characterization of Chimeric Endolysin ZAM-MSC.Iranian biomedical journal · 2025Article
- PlyNJ3: a three-domain endolysin with broad-spectrum anti-streptococcal activity and synergistic efficacy against multidrug-resistant Streptococcus suis.BMC veterinary research · 2025Article
- PlyCYU endolysin targetingApplied and environmental microbiology · 2025Article
- Discovery of potent endolysins against Pseudomonas aeruginosa and other gram-negative ESKAPE pathogens by an agar-based screening method.Scientific reports · 2025Article
- Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
165 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Lysins are highly evolved enzymes produced by bacteriophage (phage for short) to digest the bacterial cell wall for phage progeny release. In Gram-positive bacteria, small quantities of purified recombinant lysin added externally results in immediate lysis causing log-fold death of the target bacterium. Lysins have been used successfully in a variety of animal models to control pathogenic antibiotic resistant bacteria found on mucosal surfaces and infected tissues. The advantages over antibiotics are their specificity for the pathogen without disturbing the normal flora, the low chance of bacterial resistance to lysins, and their ability to kill colonizing pathogens on mucosal surfaces, a capacity previously unavailable. Thus, lysins may be a much needed anti-infective in an age of mounting antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.